PharmaCyte Biotech Statistics
Total Valuation
PMCB has a market cap or net worth of $8.89 million. The enterprise value is -$7.87 million.
Important Dates
The last earnings date was Monday, March 17, 2025, after market close.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PMCB has 6.89 million shares outstanding. The number of shares has decreased by -35.50% in one year.
| Current Share Class | 6.89M |
| Shares Outstanding | 6.89M |
| Shares Change (YoY) | -35.50% |
| Shares Change (QoQ) | -8.87% |
| Owned by Insiders (%) | 2.84% |
| Owned by Institutions (%) | 11.49% |
| Float | 6.17M |
Valuation Ratios
The trailing PE ratio is 0.92.
| PE Ratio | 0.92 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.20 |
| P/TBV Ratio | 0.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.20
| Current Ratio | 14.20 |
| Quick Ratio | 14.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 42.89% and return on invested capital (ROIC) is -5.96%.
| Return on Equity (ROE) | 42.89% |
| Return on Assets (ROA) | -4.89% |
| Return on Invested Capital (ROIC) | -5.96% |
| Return on Capital Employed (ROCE) | -10.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $4.99M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.44% in the last 52 weeks. The beta is -0.53, so PMCB's price volatility has been lower than the market average.
| Beta (5Y) | -0.53 |
| 52-Week Price Change | -39.44% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 1.69 |
| Relative Strength Index (RSI) | 43.09 |
| Average Volume (20 Days) | 18,016 |
Short Selling Information
The latest short interest is 20,228, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 20,228 |
| Short Previous Month | 26,759 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.33% |
| Short Ratio (days to cover) | 1.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.50M |
| Pretax Income | -1.14M |
| Net Income | 9.98M |
| EBITDA | n/a |
| EBIT | -4.50M |
| Earnings Per Share (EPS) | $1.29 |
Full Income StatementBalance Sheet
The company has $16.76 million in cash and n/a in debt, giving a net cash position of $16.76 million or $2.43 per share.
| Cash & Cash Equivalents | 16.76M |
| Total Debt | n/a |
| Net Cash | 16.76M |
| Net Cash Per Share | $2.43 |
| Equity (Book Value) | 40.25M |
| Book Value Per Share | 5.83 |
| Working Capital | 15.77M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |